DNDi aims to deliver from its mycetoma-specific portfolio:

 

  • An oral, safe, effective treatment.

 

The mycetoma portfolio includes:

 

Development

Development

Fosravuconazole

 

 

For more details on each project, see DNDi‘s Global Portfolio